- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Glycopeptide antibiotics.
Displaying page 1 of 1.
EudraCT Number: 2015-004814-84 | Sponsor Protocol Number: CS/2016/01 | Start Date*: 2016-05-18 |
Sponsor Name:Sint Antonius Hospital | ||
Full Title: Individualized dosing of aminoglycosides, quinolones and glycopeptide antibiotics in (morbidly) obese patients | ||
Medical condition: Morbid obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000471-20 | Sponsor Protocol Number: RIPH_2019_01 | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:CH Tourcoing | |||||||||||||
Full Title: Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-la... | |||||||||||||
Medical condition: Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000415-32 | Sponsor Protocol Number: DAL-PK-02 | Start Date*: 2022-06-07 | |||||||||||
Sponsor Name:Allergan | |||||||||||||
Full Title: Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection | |||||||||||||
Medical condition: Bacterial Infection in hospitalized children | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003227-11 | Sponsor Protocol Number: DUR001-106 | Start Date*: 2014-11-28 | ||||||||||||||||
Sponsor Name:Durata Therapeutics International B.V. | ||||||||||||||||||
Full Title: PHASE 1, OPEN LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF DALBAVANCIN IN HOSPITALIZED CHILDREN AGED 3 MONTHS TO 11 YEARS RECEIVING STANDARD INTRAVENOUS ... | ||||||||||||||||||
Medical condition: Bacterial Infection in hospitalized children | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: EE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
